A Phase 1, First-in-human Study of MORF-440 in Healthy Participants, Including Single and Multiple Ascending Dose Cohorts
Latest Information Update: 15 Oct 2025
At a glance
- Drugs LY 4292009 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors Morphic Therapeutic
Most Recent Events
- 26 May 2025 New trial record